IMMUNEONCO-B News

IMMUNEONCO-B: INSIDE INFORMATION - UPDATE ON GLOBAL REGISTRATIONAL STRATEGY FOR IMM2510 FOR NON-SMALL CELL LUNG CANCER AND TRIPLE-NEGATIVE BREAST CANCER

Sep 16 06:00 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - TRANSFER OF EQUITY INTEREST IN A SUBSIDIARY

Sep 13 10:39 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - FURTHER PAYMENT RECEIVED UNDERTHE LICENSE AND COLLABORATION AGREEMENT WITHSYNBIOTX FOR IMM2510 AND IMM27M

Sep 10 18:12 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS

Sep 9 18:04 ET

IMMUNEONCO-B: Next Day Disclosure Return

Sep 4 06:15 ET

IMMUNEONCO-B: INSIDE INFORMATION - COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY

Sep 4 06:07 ET

IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024

Sep 3 21:34 ET

IMMUNEONCO-B: INSIDE INFORMATION - THE H SHARE FULL CIRCULATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

Sep 3 05:03 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPFRONT PAYMENT RECEIVED UNDER THE LICENSE ANDCOLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510AND IMM27M

Aug 22 06:34 ET

IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024

Aug 5 21:56 ET

IMMUNEONCO-B: INSIDE INFORMATION - LICENSE AND COLLABORATION AGREEMENT WITH SYNBIOTX FOR IMM2510 AND IMM27M

Aug 1 06:34 ET

IMMUNEONCO-B: (1) RESIGNATION OF SUPERVISOR; AND (2) ELECTION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

Jul 29 18:04 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OFIMM2510 IN COMBINATION WITH IMM27M

Jul 24 05:10 ET

IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024

Jul 4 21:50 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH TISLELIZUMAB

Jul 3 05:22 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMC-002

Jun 21 06:29 ET

IMMUNEONCO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024

Jun 4 23:25 ET

IMMUNEONCO-B: VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR A PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML

Jun 2 19:20 ET

IMMUNEONCO-B: INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY

May 29 10:47 ET

IMMUNEONCO-B: List of Directors and their Role and Function

May 28 08:09 ET